Topics

FDA approves new treatment for patients with migraine

10:13 EDT 11 Oct 2019 | FDA

The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.

Original Article: FDA approves new treatment for patients with migraine

NEXT ARTICLE

More From BioPortfolio on "FDA approves new treatment for patients with migraine"

Quick Search

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...